Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
XRAY vs NVST vs ALGN vs HSIC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
Medical - Devices
Medical - Distribution
XRAY vs NVST vs ALGN vs HSIC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Equipment & Services | Medical - Devices | Medical - Distribution |
| Market Cap | $2.20B | $4.04B | $12.06B | $8.09B |
| Revenue (TTM) | $3.68B | $2.81B | $4.10B | $13.18B |
| Net Income (TTM) | $-628M | $68M | $430M | $398M |
| Gross Margin | 48.9% | 55.1% | 67.7% | 29.1% |
| Operating Margin | 4.1% | 9.0% | 14.4% | 5.8% |
| Forward P/E | 7.7x | 17.2x | 14.9x | 13.3x |
| Total Debt | $2.47B | $1.71B | $114M | $3.69B |
| Cash & Equiv. | $326M | $1.21B | $1.08B | $156M |
XRAY vs NVST vs ALGN vs HSIC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| DENTSPLY SIRONA Inc. (XRAY) | 100 | 23.6 | -76.4% |
| Envista Holdings Co… (NVST) | 100 | 114.9 | +14.9% |
| Align Technology, I… (ALGN) | 100 | 68.6 | -31.4% |
| Henry Schein, Inc. (HSIC) | 100 | 116.1 | +16.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XRAY vs NVST vs ALGN vs HSIC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
XRAY is the clearest fit if your priority is dividends.
- 5.9% yield; 23-year raise streak; the other 3 pay no meaningful dividend
NVST has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 8.3%, EPS growth 104.3%, 3Y rev CAGR 1.9%
- Lower volatility, beta 1.65, Low D/E 55.0%, current ratio 2.38x
- Beta 1.65, current ratio 2.38x
- 8.3% revenue growth vs XRAY's -3.0%
ALGN is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 10.5% margin vs XRAY's -17.1%
- 6.9% ROA vs XRAY's -11.2%, ROIC 15.4% vs 5.1%
HSIC is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.73
- 5.3% 10Y total return vs ALGN's 122.8%
- PEG 4.21 vs NVST's 11.53
- Lower P/E (13.3x vs 14.9x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.3% revenue growth vs XRAY's -3.0% | |
| Value | Lower P/E (13.3x vs 14.9x) | |
| Quality / Margins | 10.5% margin vs XRAY's -17.1% | |
| Stability / Safety | Beta 0.73 vs XRAY's 1.78, lower leverage | |
| Dividends | 5.9% yield; 23-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +44.2% vs XRAY's -16.4% | |
| Efficiency (ROA) | 6.9% ROA vs XRAY's -11.2%, ROIC 15.4% vs 5.1% |
XRAY vs NVST vs ALGN vs HSIC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
XRAY vs NVST vs ALGN vs HSIC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALGN leads in 2 of 6 categories
XRAY leads 2 • HSIC leads 1 • NVST leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HSIC is the larger business by revenue, generating $13.2B annually — 4.7x NVST's $2.8B. ALGN is the more profitable business, keeping 10.5% of every revenue dollar as net income compared to XRAY's -17.1%. On growth, NVST holds the edge at +14.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $3.7B | $2.8B | $4.1B | $13.2B |
| EBITDAEarnings before interest/tax | $424M | $342M | $790M | $1.1B |
| Net IncomeAfter-tax profit | -$628M | $68M | $430M | $398M |
| Free Cash FlowCash after capex | $104M | $220M | $717M | $561M |
| Gross MarginGross profit ÷ Revenue | +48.9% | +55.1% | +67.7% | +29.1% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +9.0% | +14.4% | +5.8% |
| Net MarginNet income ÷ Revenue | -17.1% | +2.4% | +10.5% | +3.0% |
| FCF MarginFCF ÷ Revenue | +2.8% | +7.8% | +17.5% | +4.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +0.1% | +14.4% | +6.2% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -150.0% | +130.0% | +23.6% | +14.9% |
Valuation Metrics
XRAY leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 75% valuation discount to NVST's 86.7x P/E. Adjusting for growth (PEG ratio), HSIC offers better value at 6.84x vs NVST's 58.08x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $2.2B | $4.0B | $12.1B | $8.1B |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $4.5B | $11.1B | $11.6B |
| Trailing P/EPrice ÷ TTM EPS | -3.65x | 86.73x | 29.80x | 21.56x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.68x | 17.21x | 14.85x | 13.26x |
| PEG RatioP/E ÷ EPS growth rate | — | 58.08x | — | 6.84x |
| EV / EBITDAEnterprise value multiple | 7.18x | 13.28x | 13.92x | 10.87x |
| Price / SalesMarket cap ÷ Revenue | 0.60x | 1.49x | 2.99x | 0.61x |
| Price / BookPrice ÷ Book value/share | 1.63x | 1.32x | 3.02x | 1.79x |
| Price / FCFMarket cap ÷ FCF | 21.11x | 17.54x | 24.57x | 14.12x |
Profitability & Efficiency
ALGN leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
ALGN delivers a 10.7% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-41 for XRAY. ALGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRAY's 1.84x. On the Piotroski fundamental quality scale (0–9), NVST scores 7/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -41.2% | +2.2% | +10.7% | +8.2% |
| ROA (TTM)Return on assets | -11.2% | +1.2% | +6.9% | +3.6% |
| ROICReturn on invested capital | +5.1% | +4.8% | +15.4% | +7.1% |
| ROCEReturn on capital employed | +6.1% | +4.9% | +14.5% | +9.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 7 | 4 |
| Debt / EquityFinancial leverage | 1.84x | 0.55x | 0.03x | 0.77x |
| Net DebtTotal debt minus cash | $2.1B | $496M | -$965M | $3.5B |
| Cash & Equiv.Liquid assets | $326M | $1.2B | $1.1B | $156M |
| Total DebtShort + long-term debt | $2.5B | $1.7B | $114M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | -5.12x | 12.76x | 389.13x | 4.59x |
Total Returns (Dividends Reinvested)
HSIC leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HSIC five years ago would be worth $8,746 today (with dividends reinvested), compared to $1,991 for XRAY. Over the past 12 months, NVST leads with a +44.2% total return vs XRAY's -16.4%. The 3-year compound annual growth rate (CAGR) favors HSIC at -4.0% vs XRAY's -32.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -2.8% | +12.0% | +7.9% | -8.2% |
| 1-Year ReturnPast 12 months | -16.4% | +44.2% | -2.2% | +5.9% |
| 3-Year ReturnCumulative with dividends | -69.4% | -30.3% | -45.0% | -11.7% |
| 5-Year ReturnCumulative with dividends | -80.1% | -46.6% | -71.9% | -12.5% |
| 10-Year ReturnCumulative with dividends | -74.5% | -13.1% | +122.8% | +5.3% |
| CAGR (3Y)Annualised 3-year return | -32.6% | -11.3% | -18.1% | -4.0% |
Risk & Volatility
Evenly matched — ALGN and HSIC each lead in 1 of 2 comparable metrics.
Risk & Volatility
HSIC is the less volatile stock with a 0.73 beta — it tends to amplify market swings less than XRAY's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALGN currently trades 80.8% from its 52-week high vs XRAY's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 1.65x | 1.66x | 0.73x |
| 52-Week HighHighest price in past year | $17.18 | $30.42 | $208.31 | $89.29 |
| 52-Week LowLowest price in past year | $9.85 | $16.33 | $122.00 | $61.95 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +79.8% | +80.8% | +79.0% |
| RSI (14)Momentum oscillator 0–100 | 39.2 | 55.1 | 44.6 | 39.1 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 2.4M | 1.1M | 1.2M |
Analyst Outlook
XRAY leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: XRAY as "Hold", NVST as "Hold", ALGN as "Buy", HSIC as "Hold". Consensus price targets imply 22.6% upside for HSIC (target: $86) vs 11.2% for NVST (target: $27). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $13.40 | $27.00 | $203.60 | $86.43 |
| # AnalystsCovering analysts | 31 | 19 | 33 | 32 |
| Dividend YieldAnnual dividend ÷ price | +5.9% | — | — | — |
| Dividend StreakConsecutive years of raises | 23 | — | — | 1 |
| Dividend / ShareAnnual DPS | $0.64 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.1% | +3.9% | +10.5% |
ALGN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XRAY leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
XRAY vs NVST vs ALGN vs HSIC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is XRAY or NVST or ALGN or HSIC a better buy right now?
For growth investors, Envista Holdings Corp (NVST) is the stronger pick with 8.
3% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Align Technology, Inc. (ALGN) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XRAY or NVST or ALGN or HSIC?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus Envista Holdings Corp at 86. 7x. On forward P/E, DENTSPLY SIRONA Inc. is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Henry Schein, Inc. wins at 4. 21x versus Envista Holdings Corp's 11. 53x.
03Which is the better long-term investment — XRAY or NVST or ALGN or HSIC?
Over the past 5 years, Henry Schein, Inc.
(HSIC) delivered a total return of -12. 5%, compared to -80. 1% for DENTSPLY SIRONA Inc. (XRAY). Over 10 years, the gap is even starker: ALGN returned +122. 8% versus XRAY's -74. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XRAY or NVST or ALGN or HSIC?
By beta (market sensitivity over 5 years), Henry Schein, Inc.
(HSIC) is the lower-risk stock at 0. 73β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 144% more volatile than HSIC relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — XRAY or NVST or ALGN or HSIC?
By revenue growth (latest reported year), Envista Holdings Corp (NVST) is pulling ahead at 8.
3% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: Envista Holdings Corp grew EPS 104. 3% year-over-year, compared to 0. 5% for Align Technology, Inc.. Over a 3-year CAGR, ALGN leads at 2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — XRAY or NVST or ALGN or HSIC?
Align Technology, Inc.
(ALGN) is the more profitable company, earning 10. 2% net margin versus -16. 3% for DENTSPLY SIRONA Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALGN leads at 15. 3% versus 5. 7% for HSIC. At the gross margin level — before operating expenses — ALGN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is XRAY or NVST or ALGN or HSIC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Henry Schein, Inc. (HSIC) is the more undervalued stock at a PEG of 4. 21x versus Envista Holdings Corp's 11. 53x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, DENTSPLY SIRONA Inc. (XRAY) trades at 7. 7x forward P/E versus 17. 2x for Envista Holdings Corp — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HSIC: 22. 6% to $86. 43.
08Which pays a better dividend — XRAY or NVST or ALGN or HSIC?
In this comparison, XRAY (5.
9% yield) pays a dividend. NVST, ALGN, HSIC do not pay a meaningful dividend and should not be held primarily for income.
09Is XRAY or NVST or ALGN or HSIC better for a retirement portfolio?
For long-horizon retirement investors, Henry Schein, Inc.
(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Envista Holdings Corp (NVST) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HSIC: +5. 3%, NVST: -13. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between XRAY and NVST and ALGN and HSIC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XRAY is a small-cap income-oriented stock; NVST is a small-cap quality compounder stock; ALGN is a mid-cap quality compounder stock; HSIC is a small-cap quality compounder stock. XRAY pays a dividend while NVST, ALGN, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Compare HSIC vs DXPE
DXPE is one of the most direct listed alternatives to HSIC.
Compare ALGN vs IDXX
IDXX overlaps with ALGN in an adjacent operating segment worth comparing.
Add HOLX to This Comparison
HOLX is the strongest missing peer across the current compare set.